Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Avadel Pharmaceuticals Plc (NQ: AVDL )

8.170 USD +0.290 (+3.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Avadel Pharmaceuticals Plc

< Previous 1 2 3 4 Next >
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10th
From GlobeNewswire News Releases
Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting
From GlobeNewswire News Releases
Avadel to Present New Data from its Pivotal REST-ON Phase 3 Study of FT218 at the American Academy of Neurology Annual Meeting 2021
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Participate in a Fireside Chat at Stifel’s Third Annual CNS Day on March 31st
From GlobeNewswire News Releases
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
From GlobeNewswire News Releases
Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2021 Young Investigators Research Forum
Avadel to support AASM Foundation scholarships and training for early career sleep researchers 
From GlobeNewswire News Releases
Avadel Pharmaceuticals Announces Publication of Once-Nightly FT218 Pharmacokinetic Studies
From GlobeNewswire News Releases
Thinking about buying stock in Phio Pharmaceuticals, SRAX Inc, KemPharm, Avadel Pharmaceuticals, or Neovasc Inc?
InvestorsObserver issues critical PriceWatch Alerts for PHIO, SRAX, KMPH, AVDL, and NVCN. 
From PR Newswire
Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy
FT218 assigned PDUFA target action date of October 15, 2021 
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Participate in Fireside Chats at Upcoming March 2021 Investor Conferences
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Provide a Company Update and Report Fourth Quarter and Full Year 2020 Financial Results, on March 9th
From GlobeNewswire News Releases
Avadel Pharmaceuticals Appoints Richard Kim as Chief Commercial Officer to Lead the Commercial Launch of Once-Nightly FT218
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference
From GlobeNewswire News Releases
Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA
From GlobeNewswire News Releases
Avadel Pharmaceuticals Added to NASDAQ Biotechnology Index
From GlobeNewswire News Releases
Avadel Pharmaceuticals Appoints Dr. Jennifer Gudeman as Vice President of Medical and Clinical Affairs
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Present at Upcoming December 2020 Investor Conferences
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Present at Upcoming November 2020 Investor Conferences
From GlobeNewswire News Releases
Avadel Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Update on FT218 Development Program
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 9th
From GlobeNewswire News Releases
Thinking about buying stock in Avadel Pharmaceuticals, Nikola Corp, Agile Therapeutics, Biocept Inc, or Uber Technologies?
InvestorsObserver issues critical PriceWatch Alerts for AVDL, NKLA, AGRX, BIOC, and UBER. 
From PR Newswire
Avadel to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
From GlobeNewswire News Releases
Avadel Pharmaceuticals Announces FT218 Leadership Transition
From GlobeNewswire News Releases
Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference
From GlobeNewswire News Releases
Avadel Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent Business Update
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10th
From GlobeNewswire News Releases
Avadel Pharmaceuticals Announces First Patient Dosed in Open-Label Extension/Switch Study of Investigational Once-Nightly FT218 as a Potential Treatment for Excessive Daytime Sleepiness and Cataplexy
From GlobeNewswire News Releases
Avadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42.0 Million
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Present at BIO Digital
From GlobeNewswire News Releases
Avadel Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
From GlobeNewswire News Releases
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.